Status:
COMPLETED
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hypercholesterolemia
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release. There will be 6 scheduled clini...
Eligibility Criteria
Inclusion
- Patient is an appropriate candidate for niacin therapy (at risk for heart disease) and triglycerides \< 500 mg/dL
Exclusion
- Patients with a history of any cardiovascular event directly linked to atherosclerosis with a low density lipoprotein-cholesterol (LDL-C) \>/= 130 mg/dL and/or not on a statin
- Patients with diabetes and LDL-C \>/= 130 mg/dL. Patients with \>/= 2 heart disease risk factors and LDL-C \>/= 160 mg/dL.
- Patients who have had a cardiovascular event (e.g., heart attack, stroke) within the previous 3 months.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT00378833
Start Date
July 1 2006
End Date
March 1 2007
Last Update
February 16 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.